These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. Mintzer JE J Clin Psychiatry; 2001; 62 Suppl 21():23-5. PubMed ID: 11584984 [TBL] [Abstract][Full Text] [Related]
50. Neuroleptic malignant syndrome with use of quetiapine in mental retardation. Dan A; Bharadwaj R; Grover S Psychiatry Clin Neurosci; 2009 Apr; 63(2):255-6. PubMed ID: 19335404 [No Abstract] [Full Text] [Related]
51. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Meco G; Bernardi S Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377 [TBL] [Abstract][Full Text] [Related]
52. Challenges in the management of psychotic symptoms in long-term care. Gravenstein S; Beier M; Singer C J Am Med Dir Assoc; 2003; 4(4 Suppl):H17-20. PubMed ID: 12857363 [No Abstract] [Full Text] [Related]
53. Treatment of Psychosis in Parkinson's disease and sudden death. Kyle K; Bronstein JM Parkinsonism Relat Disord; 2020 Oct; 79():127. PubMed ID: 32943345 [No Abstract] [Full Text] [Related]
54. A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. Kurhan F; Akın M Curr Alzheimer Res; 2023; 20(6):403-408. PubMed ID: 37641988 [TBL] [Abstract][Full Text] [Related]
55. Pimavanserin for Parkinson Disease Psychosis. Mohanty D; Sarai S; Naik S; Lippmann S Prim Care Companion CNS Disord; 2019 Apr; 21(2):. PubMed ID: 31050230 [No Abstract] [Full Text] [Related]